Company builds on its strengths to advance patient access, product innovation, culture and inclusion and diversity
NORTHAMPTON, MA / ACCESSWIRE / April 8, 2024 / Bristol Myers (NYSE:BMY) Squibb Company
Bristol Myers Squibb¯(NYSE: BMY) today published its 2023 Environmental, Social, and Governance (ESG) Report detailing the company's meaningful progress, evolved strategy, and aspirational goals toward its ESG efforts. The company's ESG strategy is embedded in its mission to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases.
"For more than 130 years, BMS has enabled positive change for our patients around the world. As we navigate an increasingly complex global landscape, our ESG strategy has never been more important to driving long-term business value and fulfilling our purpose," said Christopher Boerner, Ph.D., Board Chair & Chief Executive Officer, Bristol Myers Squibb. "We recognize ESG is a journey of continuous improvement, and our entire team is committed to advancing sustainability."
In 2023, BMS conducted a global ESG materiality assessment to understand evolving stakeholder views and ensure its business priorities reflect the rapidly changing landscape. These insights enabled the company to evolve its ESG strategy, focusing on three key pillars: advancing patient health around the world; expanding the boundaries of science; and fostering a high-performing and inclusive global workforce. At the same time, BMS will continue to amplify its strong performance across material topics such as patient safety and product quality, ethics and conduct, as well as environmental sustainability.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com¯or follow us on LinkedIn, Twitter, YouTube, Facebook (NASDAQ:META) and¯Instagram.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the Company's goals, strategies, and performance in accordance with its 2023 Environmental, Social, and Governance (ESG) Report. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb's business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2023, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.
MEDIA CONTACT:
Media@bms.com
Read More
View additional multimedia and more ESG storytelling from Bristol Myers Squibb Company on 3blmedia.com.
Contact Info:
Spokesperson: Bristol Myers Squibb Company
Website: https://www.3blmedia.com/profiles/bristol-myers-squibb-company
Email: info@3blmedia.com
SOURCE: Bristol Myers Squibb Company